Acadia Q3 10-Q: Revenue Up 23% to $342M, Net Income Down to $53.5M
ACAD sits 19% above its 52-week low of $18.39 on elevated volume (2.6× avg).
Summary
Acadia's Q3 10-Q shows revenue up 23% to $342.3 million but net income down to $53.5 million as SG&A and taxes rose, alongside $976.4 million in cash and a trofinetide patent extension to 2041.
Key Events · Earnings and Guidance · ACAD
-
Q3 Revenue Grows 23% to $342.3M
Total revenues rose to $342.3 million from $278.6 million a year earlier, with NUPLAZID at $202.2 million and DAYBUE products at $140.1 million.
-
Net Income Falls to $53.5M
Net income dropped to $53.5 million ($0.31 per diluted share) from $71.8 million ($0.42) as SG&A rose to $159.2 million from $133.4 million and tax expense was $26.9 million versus a $27.2 million benefit.
-
Cash and Investments Reach $976.4M
Cash, cash equivalents and investment securities totaled $976.4 million at September 30, 2026, up $156.7 million from December 31, 2025, on $146.3 million of nine-month operating cash flow; management says this funds operations beyond the next 12 months.
-
Trofinetide Patent Extended to 2041
A September 2026 USPTO notice of allowance for weight-banded trofinetide dosing extends U.S. patent protection from July 2036 to March 2041, with intangible amortization now running through March 2041.
Analysis · ACAD · Life Sciences
Top-line growth is real: Q3 sales rose 23% to $342.3 million on NUPLAZID and DAYBUE strength. The bottom line moved the other way, however, with net income falling to $53.5 million ($0.31 per share) from $71.8 million ($0.42) a year earlier as selling, general and administrative costs jumped to $159.2 million from $133.4 million and the tax line swung to a $26.9 million expense from a $27.2 million benefit. The balance sheet offers reassurance: $976.4 million in cash and investments after $146.3 million of nine-month operating cash flow, which management says funds operations beyond the next 12 months. Two items also extend the franchise. A USPTO allowance on weight-banded trofinetide dosing pushes U.S. patent protection to March 2041, and the Zydus patent case settled with a generic 34 mg launch date of April 1, 2032.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACAD was trading at $21.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $18.39 to $30.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.